Unicycive(US:UNCY) Prnewswire·2025-10-02 12:04Core Viewpoint - A class action lawsuit has been filed against Unicycive Therapeutics, Inc. for allegedly making false and misleading statements regarding its FDA approval prospects for a treatment related to hyperphosphatemia in chronic kidney disease patients on dialysis [1][2]. Group 1: Lawsuit Details - The class period for the lawsuit is from March 29, 2024, to June 27, 2025, with a deadline for lead plaintiff appointments set for October 14, 2025 [2]. - The complaint alleges that Unicycive was overly optimistic about the chances of FDA approval for its treatment, leading to materially misleading public statements throughout the class period [2]. Group 2: Shareholder Participation - Shareholders who purchased shares during the specified class period are encouraged to contact the DJS Law Group for potential lead plaintiff appointments, although this is not required to participate in any recovery [2][3]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates on the case's status, with no cost or obligation to participate [3]. Group 3: DJS Law Group's Role - DJS Law Group specializes in securities class actions and corporate governance litigation, focusing on enhancing investor returns through advocacy [4].